SCHEDULE 13G/A: Tang Capital Entities Disclose 6.4% Passive Stake in Precision BioSciences

Tang Capital Management, LLC and affiliated entities, including Kevin Tang, have disclosed a combined 6.4% beneficial ownership stake in Precision BioSciences, Inc. as of March 31, 2025, held for passive investment purposes.

Summary

• Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP collectively reported beneficial ownership of 673,332 shares of Precision BioSciences, Inc. Common Stock.
• This represents 6.4% of the outstanding Common Stock, based on 10,481,931 shares outstanding as of March 20, 2025, as reported in the Issuer's Annual Report on Form 10-K.
• The shares are held with shared voting and dispositive power among Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP.
• Specifically, Tang Capital Partners, LP beneficially owns 378,682 shares (3.6%), and Tang Capital Partners International, LP beneficially owns 294,650 shares (2.8%).
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to their previously reported ownership or group structure.
• The reporting persons certify that the securities were not acquired and are not held for the purpose or with the effect of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 6

Explanation: The filing is a routine regulatory disclosure of beneficial ownership. The presence of a significant stake by an investment group like Tang Capital could be viewed as a positive signal of investor confidence, but the document itself contains no performance-related information.

Positives

• A significant investment group, Tang Capital, holds a 6.4% stake, potentially signaling confidence in Precision BioSciences, Inc.

Risks

• The reporting persons certify that the shares are not held for the purpose of changing or influencing control of the issuer, except for activities related to nominations under Rule 240.14a-11, which could imply potential shareholder activism for board seats.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes and potential for shareholder activism related to board nominations.

Key Dates

Keywords

Precision BioSciences, Common Stock, Schedule 13G, Beneficial Ownership, Tang Capital Management, Kevin Tang, Shareholder Stake, SEC Filing, Investment, Biotechnology